Chemotherapy-induced Diarrhea Epidemiology Forecast 2024-2032

Chemotherapy-induced Diarrhea Epidemiology Forecast Report Coverage

Expert Market Research's “Chemotherapy-induced Diarrhea Epidemiology Forecast Report 2024-2032” offers comprehensive information on the prevalence and demographics of chemotherapy-induced diarrhea. It projects the future incidence and prevalence rates of chemotherapy-induced diarrhea across various populations. The study covers age, gender, and type as major determinants of the chemotherapy-induced diarrhea-affected population. The report highlights patterns in the prevalence of chemotherapy-induced diarrhea over time and projects future trends based on multiple variables.

Chemotherapy-induced Diarrhea: Disease Overview

Chemotherapy-induced diarrhea is a common side effect of many chemotherapy agents and is responsible for significant morbidity and mortality. Certain chemo treatments cause diarrhea as they not only destroy cancer cells but also target rapidly dividing healthy cells such as the ones lining the digestive tract. This can lead to dehydration and malnourishment, making the individual feel sick along with potentially intensifying other side effects of chemotherapy.

Common symptoms include frequent loose or watery stools, abdominal cramps, electrolyte imbalances, and urgency to have bowel movements, among others. Specific drugs and regimens are more commonly linked to causing chemotherapy-induced diarrhea such as iIrinotecan, which is known for high incidence rates of acute and delayed diarrhea, and fluorouracil (5-FU), which often causes gastrointestinal side effects.

Chemotherapy-induced Diarrhea: Treatment Overview

Although diarrhea is typically a relatively minor side effect of chemotherapy, some people experience serious symptoms. It can also be fatal as severe dehydration can result in organ damage and death. Diarrhea medications such as loperamide are usually prescribed to patients to slow diarrhea and prevent dehydration. Other common drugs include diphenoxylate and octreotide. If the patient has very severe diarrhea, the healthcare provider may change the dose of the chemotherapy agent.

Epidemiology

The chemotherapy-induced diarrhea epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for chemotherapy-induced diarrhea by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chemotherapy-induced diarrhea and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium states that chemotherapy and targeted therapies are linked to gastrointestinal (GI) side effects, including diarrhea, affecting 50% to 80% of the cancer patients receiving treatment.
• According to a study published in the Annals of Oncology (2018), the reported rate of diarrhea in cancer patients receiving neoadjuvant treatment for breast cancer was as high as 47%, with low rates of severe cases (grades 3 and 4). Further, diarrhea as a side effect is most commonly observed when 5-fluorouracil (5-FU) is given together with leucovorin (LV) to the patient.
• The frequency of severe (grade 3 or 4) diarrhea in treatment regimens containing fluoropyrimidine with irinotecan ranges from 5% to 44%, depending on the dosage of the chemotherapy agent, the specific medications used, and the schedule of administration.
• In a 2020 study of 62 women with metastatic breast cancer, 68% experienced chemotherapy-induced diarrhea (CID) at some point, with 19% reporting it at each time point.

Country-wise Chemotherapy-induced Diarrhea Epidemiology

The chemotherapy-induced diarrhea epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of chemotherapy-induced diarrhea varies between countries due to differences in clinical guidelines, access to supportive care, patient profile, and age distribution, among others, in different regions. Countries with advanced healthcare systems often have better resources for managing the side effects of this condition, which are likely to lead to improved patient outcomes and lower reported incidences of chemotherapy-induced diarrhea.

Country Specific Stats:

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chemotherapy-induced diarrhea based on several factors.
• Chemotherapy-induced Diarrhea Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population, the unmet needs of chemotherapy-induced diarrhea are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of chemotherapy-induced diarrhea epidemiology in the 8 major markets?
• What will be the total number of patients with chemotherapy-induced diarrhea across the 8 major markets during the forecast period?
• What was the country-wise prevalence of chemotherapy-induced diarrhea in the 8 major markets in the historical period?
• Which country will have the highest number of chemotherapy-induced diarrhea patients during the forecast period of 2024-2032?
• Which key factors would influence the shift in the patient population of chemotherapy-induced diarrhea during the forecast period of 2024-2032?
• What are the currently available treatments for chemotherapy-induced diarrhea?
• What are the disease risks, signs, symptoms, and unmet needs of chemotherapy-induced diarrhea?

Related Reports

Chemotherapy Induced Neutropenia Market